Cem Akin, MD, PhD

Dr. Cem Akin is a clinician-scientist and a Professor of Medicine at the University of Michigan Division of Allergy and Immunology.  He obtained his Internal Medicine training and PhD in Microbiology and Immunology from the University of Louisville and completed his fellowship at NIAID/ NIH in Allergy and Clinical Immunology.

He is recognized for his work on mast cell disorders including mastocytosis, mast cell activation syndromes, and anaphylaxis.  As an Associate Professor at Harvard Medical School, he established the first multidisciplinary mastocytosis center at Brigham and Women’s Hospital.  His clinical interests include tyrosine kinase inhibitor and other novel treatments for indolent systemic mastocytosis, tryptase, and other biomarkers for mast cell disease, and pathophysiology and treatment of anaphylaxis.

Dr. Akin is a co-author of the current WHO diagnostic criteria and classification of mastocytosis and has published over 200 scientific papers and book chapters on mastocytosis. He was awarded the Researcher of the Year and the ECNM Medal and Trophy in 2022 by the European Competence Network on Mastocytosis.  He served on the editorial board of The Journal of Allergy and Clinical Immunology and Blood, is a past President of the Michigan Allergy Society, and currently serves of the Board of Directors of the American Academy of Allergy, Asthma, and Immunology (AAAAI) and also as Vice-President of the American Initiative in Mast Cell Diseases (AIM).  He enjoys teaching fellows, conducting clinical research, and seeing a diverse population of allergy patients at the University of Michigan.